Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70500 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Pei-Chien Tsai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Cardiovascular Diseases, Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Kaohsiung Medical University, Kaohsiung Medical University Hospital, National Sun Yat-sen University and Kaohsiung Medical University Joint Research Project.
Abstract (Originalsprache)
Background
Steatotic liver disease (SLD) and cardiometabolic risk factors (CMRFs) are common in chronic hepatitis C (CHC). The risk of major adverse cardiovascular events (MACEs) after sustained virological response (SVR) remains elusive.
Aims
This study assessed the impact of CMRFs on cardiovascular outcomes in CHC patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) after achieving SVR.
Methods
We recruited SLD patients from the nationwide multicenter cohorts in Taiwan. Their CMRFs and fibrosis stage were assessed after SVR. Competing risk analyses, including Grey's method and Cox regression, were performed to estimate cardiovascular outcomes.
Results
Among 8755 patients, 624 developed MACEs during a mean follow‐up of 3.9 years. The incidence of MACEs was significantly higher in patients with MASLD than in the simple SLD group (190.2 vs. 84.0 per 10,000 person‐years, p < 0.001). Age, advanced fibrosis, chronic kidney disease (CKD), and CMRFs burden were independently associated with MACEs. The MACEs risk increased with CMRFs burden, with adjusted hazard ratios from 1.72 for one CMRF to 2.33 for ≥ four CMRFs. The risk was significantly higher in patients without advanced fibrosis or CKD than in their counterparts.
Conclusions
CMRFs burden, advanced fibrosis, and CKD predicted MACEs in CHC patients with MASLD after achieving SVR. CMRFs monitoring and management should be prioritised in high‐risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Hepatitis Center and Center for Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Center of Excellence for Metabolic Associated Fatty Liver Disease and School of Medicine, College of Medicine, National Sun Yet-Sen University, Kaohsiung, Taiwan.
ORCID-Profile: Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Tyng-Yuan Jang, Po-Cheng Liang, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
Förderung
- Kaohsiung Medical University
- Kaohsiung Medical University Hospital
- National Sun Yat-sen University and Kaohsiung Medical University Joint Research Project
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Zitieren
APA
Tsai, P. C., Huang, C. F., Yeh, M. L., Wei, Y. J., Wang, C. W., Jang, T. Y., Liang, P. C., Lin, Y. H., Dai, C. Y., Huang, J. F., Chuang, W. L., Yu, M. L., & TACR and T‐COACH Study Groups (2025). Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70500
Vancouver
Tsai PC, Huang CF, Yeh ML, Wei YJ, Wang CW, Jang TY, et al. Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70500
BibTeX
@article{Tsai2025,
author = {Tsai, Pei-Chien and Huang, Chung-Feng and Yeh, Ming-Lun and Wei, Yu-Ju and Wang, Chih-Wen and Jang, Tyng-Yuan and Liang, Po-Cheng and Lin, Yi-Hung and Dai, Chia-Yen and Huang, Jee-Fu and Chuang, Wan-Long and Yu, Ming-Lung and TACR and T‐COACH Study Groups, TACR and T‐COACH Study Groups},
title = {Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70500}
}
EUVIMED